cyrilzakka/clinical-trials huggingface dataset:
Oscillation Mechanics of the Respiratory System Asbestos Exposed: Early Diagnosis

Inhalation of dust containing asbestos results in a process of interstitial pulmonary fibrosis called asbestosis. The Forced Oscillation Technique (FOT) evaluates the respiratory mechanics describing resistive, elastic and inertial properties. We believe that this technique may contribute to the early diagnosis of asbestosis.

The aims of this study were (1) to use the FOT to analyze how respiratory mechanics is affected in patients with asbestos exposed, (2) to identify the best FOT parameters for the diagnosis of respiratory changes in these patients (3) Assess whether the presence of obstructive changes is associated with the smoking habit.The control group (CG) included 24 subjects with normal spirometric data and without a history of smoking or pulmonary disease formed by workers and students UERJ and FioCruz. Volunteers with asbestos exposure were from the Department of CESTEH/ FioCruz, totaling 24 exposed and 7 with diagnoses of asbestosis.

The diagnosis of asbestosis was established based on a history of substantial exposure to asbestos dusts and compatible radiological features, together with exclusion of other competing diagnoses.

The tests included a standardized questionnaire on respiratory symptoms, clinical evaluation; Plain radiography of the chest; FOT, plethysmography and spirometry, in that order.

Eligibility Criteria:
Inclusion Criteria:

* diagnosis of asbestosis

Exclusion Criteria:

* other diseases
The Use of Daclizumab and Anti-Thymocyte Globulin in Lung Transplantation

The purpose of this study is to compare outcomes in patients undergoing lung transplantation, using 2 different induction therapies. Primary outcome is survival and secondary outcomes include freedom from infection and freedom from rejection.

Acute and chronic allograft rejection are two of the common problems limiting and complicating the utility of lung transplantation. The timing and frequency of acute rejection has been shown to be a significant risk factor for the development of chronic allograft rejection. As an adjunct to standard triple immunosuppressive therapy, induction therapy is thought to decrease the incidence of acute rejection.Daclizumab is an interleukin 2 receptor (IL-2) antagonist which is FDA approved as an immunosuppressive agent. Thymoglobulin is an anti-lymphocyte immunosuppressive agent that has been shown in other solid organ transplant studies to be successful in delaying the first episode of rejection but has not decreased the incidence of Obliterative Bronchiloitis (chronic rejection)in lung transplantation.

Eligibility Criteria:
Inclusion Criteria:

* All patients accepted and listed for lung transplantation will be considered for randomization

Exclusion Criteria:

* Patients who demonstrate hemodynamic instability, requiring inotropes for greater than 48 hours prior to transplant
* Severe reperfusion pulmonary edema or primary graft dysfunction requiring FiO2 of \> 50% and PEEP \> 10 cm for greater than 48 hours prior to transplant
* Preoperative renal insufficiency (CrCl \< 50 gm.d or serum creatinine \> 2.0)
* Pre-operative panel reactive antibodies PRA
* Preoperative recipient bacterial or fungal colonization
* Preoperative antimicrobial suppressive therapy
A Multicenter Analysis of Levonorgestrel-Intrauterine System (LNG-IUS) Use in the Postpartum Period

The primary objective of the investigators study is to determine if there is a difference in continuation rates at six months in women who are randomized to have the Levonorgestrel Intrauterine System (LNG-IUS) inserted at two possible time periods: Immediate (defined as after delivery of placenta to 72 hours postpartum) or Interval (defined as after 6 weeks postpartum).

The control arm of our study will be women who are randomized to receive LNG-IUS in the Interval time period. The study arm will consist of women randomized to receiving Immediate placement.

The investigators hypothesize that Immediate placement of IUD in the postpartum period will result in a 20% decrease in continuation rates at six months compared to Interval placement.

Secondary outcome measures that we will obtain include:

* Pain at the time of placement
* Postpartum Depression
* Breastfeeding status
* Postpartum weight retention
* Expulsion Rates
* Bleeding Profile
* Uterine Infection(Endometritis)

Eligibility Criteria:
Inclusion Criteria:

* All women \>37 weeks gestation who desire LNG-IUS for postpartum contraception who do not have a contraindication as described below will be offered participation in our study.

Exclusion Criteria:

Contraindications to the LNG-IUS include:

* Pregnancy or suspicion of pregnancy
* Congenital or acquired uterine anomaly including fibroids if they distort the uterine cavity
* Postpartum endometritis within the past 3 months
* Known or suspected uterine or cervical neoplasia or unresolved, abnormal pap smear
* untreated acute cervicitis or vaginitis including bacterial vaginosis or other lower genital tract infections
* acute liver disease or liver tumor
* hypersensitivity to any component of the product
* known or suspected carcinoma of the breast

Any of these conditions would exclude the patient from receiving these forms of contraception in our study.

In addition the following intrapartum findings, the following would exclude the patient:

* Delivery \<37 weeks
* Intrapartum chorioamnionitis (defined as maternal fever \>100.4 and two of the following conditions: Maternal leukocytosis (greater than 15,000 cells/cubic millimeter), Maternal tachycardia (greater than 100 beats/minute), Fetal tachycardia (greater than 160 beats/minute), Uterine tenderness, Foul odor of the amniotic fluid
* Postpartum Hemorrhage (defined as \>500cc EBL for spontaneous vaginal delivery or \>1000cc for cesarean delivery)
Effectiveness of Telerehabilitation on Scleroderma

The effects of exercises performed by telerehabilitation on individuals with hand-affected scleroderma on range of motion, grip strength, function, sensation, daily life activities and general health will be compared with the effects of traditional physiotherapy practices.


Eligibility Criteria:
Inclusion Criteria:

* Having been diagnosed with scleroderma
* Stability of medical treatments
* To be able to adapt to the exercises

Exclusion Criteria:

* The patient has a history of neurological disease or trauma that may affect his symptoms
* Systemic involvement that affects the treatment process
* Being in the active phase of the disease
Civamide Nasal Solution for the Treatment of Dry Eye

Keratoconjunctivitis sicca (KCS) or Dry Eye Syndrome is a disease of the surface of the eye, tear film, and related ocular tissues. Millions of people suffer from one form of the disease or another and its prevalence increases with age. Dry Eye Syndrome sufferers experience a broad range of symptoms including discomfort, irritation, burning, itching, redness, pain, gritty feeling, foreign body sensation, blurred vision and ocular fatigue. Civamide is a TRPV-1 receptor modulator that causes the initial stimulation of neuropeptide release and subsequent desensitization to further stimulation of the trigeminovascular system. This provides a pharmacological rational for intranasal route of administration for disorders mediated by the trigeminal nerve or involving the cranial nerve. In nine clinical studies of Civamide Nasal Solution, over 50% of the nearly 300 patients who received Civamide via intranasal administration experienced lacrimation (tearing). This led to the hypothesis that Civamide Nasal Solution might be an appropriate treatment for Dry Eye Syndrome.


Eligibility Criteria:
Inclusion Criteria:

1. Patients must be aged 18 years or older.
2. Patients must have documented moderate to severe evaporative Dry Eye Syndrome for at least 6 months.
3. Patients must have a Schirmer (with anesthesia) of ≤ 8 per 5 minutes in at least one eye at Screening and Baseline (Day 1).
4. Patients must have a calculated overall score on the OSDI of \>0.1 with no more than three responses of not applicable (N/A) at Screening and Baseline (Day 1).
5. Patients must have normal lid position and closure.
6. Women must be post-menopausal ≥ 1 year, or surgically sterilized. If not, a negative urine pregnancy test is required within 14 days of Day 1.
7. Informed consent must be provided.

Exclusion Criteria:

1. Patients with severe inflammatory Dry Eye Syndrome.
2. Patients with Dry Eye Syndrome secondary to Sjögren's Syndrome.
3. Patients with Schirmer (with anesthesia) of \>8 per 5 minutes in both eyes.
4. Patients who are allergic to Civamide or any similar products, or excipients of Civamide Nasal Solution 0.01%.
5. Patients with history of previous ocular surgery or trauma.
6. Patients who require concurrent ocular medication for any eye disorder.
7. Patients who have used Restasis®, serum tears, or oral omega 3 supplements during the last 30 days or oral cyclosporine during the last 90 days.
8. Patients who are receiving or have received within 30 days any experimental systemic medication.
Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome

This study aims to find the change of serum wnt effectory moleculars and the association with Hs-CRP，cTnI and Prognosis in Patients with Acute Coronary Syndrome.

It has been reported that wnt effecory moleculars (wnt2, wnt4, wnt11,wnt10b, DKK1, DKK2) increased in myocardium at acute phase after myocardium infarction in animal experiment. These moleculars can be detected in serum or plasma from human subjects. However, there is few relevant studies about wnt2 and wnt4 concentration in patients with acute coronary syndrome. This study valuates the serum wnt2 and wnt4 concentration in patients with acute coronary syndrome. It will possibly enable to find the relationship between serum wnt2 or wnt4 concentration and Hs-CRP, cTnI and prognosis in patients with Acute Coronary Syndrome.

Eligibility Criteria:
Inclusion Criteria:

.diagnosed as acute coronary syndrome, including STEMI and NST-ACS.

* with left ventricular ejection fraction（LVEF）\>=45%
* written informed consents are obtained
* admitted within 24 hours after chest pain attacked

Exclusion Criteria:

* • complicated with rheumatic heart disease, coronary arteritis, hypertrophic cardiomyopathy or dilated cardiomyopathy

  * complicated with malignant tumor,the immune system diseases, blood system diseases, recently (within 2 weeks) taking glucocorticoid drugs, the use of immunosuppressive agents and cerebral infarction
  * with acute or chronic infection, surgery or trauma in the last month
  * secondary hypertension, severe liver dysfunction,severe renal insufficiency
  * with abnormal thyroid function or allergy to iodine agent refusal to sign the informed consent
The Neural Substrates for Working Memory Training

This study aims to conduct a contrast study on the characteristics of functional and structural connectivity of neural networks of working memory in patients with acquired brain injury versus normal controls, using resting-state functional connectivity magnetic resonance imaging, task-specific functional magnetic resonance imaging and diffusion tensor imaging, combined with cognitive behavioral examinations. Another purpose is to reveal the characteristics of dynamic change of neural networks of working memory pre- and post-intervention in patients with working memory dysfunction.


Eligibility Criteria:
Inclusion Criteria:

* Right handedness
* Diagnosis of traumatic brain injury or stroke
* Course of disease within one year
* The score of MoCA test \> 24
* Able to understand instructions

Exclusion Criteria:

* Aphasia, unilateral spatial neglect, agnosia, apraxia
* Hearing impairment or visual impairment
* History of taking psychiatric drugs
Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control

Low dose of aspirin is the main cause of gastro-duodenal ulcer. The best prevention is not definite particularly in patients without history of ulcer and infected by H. pylori.The aim of the study is to evaluate the gastric damage induced by aspirin in patients with H. pylori infection but who have any history of ulcer.

The aim of the study is to compare the protective effect of H. pylori eradication versus Pantoprazole versus placebo on the gastric damage induced by low dose of aspirin. Treatment are attributed by randomisation. Patients are followed for 6 months and gastric damage are evaluated by endoscopy at the end of this period.

Eligibility Criteria:
Inclusion Criteria:

* Patients of more than 18 years old
* Coronarography or coronary imaging or supra-aortic arterial trunks ultrasound examination performed since less 7 months and having at least an arterial vascular stenosis
* Indication for aspirin treatment for at least 12 months (at the moment of the visit of inclusion) at a posology from 80 to 125 mg per day. The treatment must be prescribed since less than 7 months.
* Patient who had since less 7 month a positive Helicobacter Pylori serology.
* For the women in age to procreate, effective mode of contraception (oral contraception, surgical sterilization, coil)
* Patient having given an informed consent according to recommendation of the CPP (institutional ethical committee).

Exclusion Criteria:

* treatment by anti-coagulant, whatever its nature and its posology, by proton pump inhibitor, H2 receptor antagonists or antiacid having to be continued beyond the day of inclusion
* Treatment by methotrexate in progress or stopped since less 3 months.
* Time of more 7 months enters the beginning of the treatment by aspirin and the visit of inclusion
* Treatment by NSAID (even occasional or self medication) under or stopped since less 3 months.
* Treatment by anti-platelet drug (clopidogrel, ticlopidine, flurbiprofen, dipyridamole or antagonist of receptor GPIIb/IIIa) in progress or stopped since less than 10 days.
* Patient with a serious pathology compromising survival in the 6 month to come.
* Patient with renal or respiratory insufficiency or a hepatic pathology having a clinical repercussion.
* History of surgery of esophagus, stomach or duodenum.
* History of digestive tract bleeding or gastro-duodenal ulcer or esophagal ulcerating proven by endoscopy.
* Allergy known to clarithromycin.
* Psychiatric disorder not controlled by treatment.
* Patients all ready include in a therapeutic protocol or to be followed for 6 month.
* Alcohol consumption higher than 100gr. per day.
* Patient non suitable for participating in the protocol or to be followed for 6 month.
* History of intolerance to salicylate.
* Constitutional or acquired hemorrhagic disease
* Pregnant woman or nursing.
* Patient in emergency, people hospitalized without their assent, people without freedom, people without social health insurance.
A Clinical Trial of a Psycho-educational Intervention to Improve Pain Management After Day Surgery

Evidence indicates that postoperative pain after day surgery is inadequately controlled. Patients have different experiences and knowledge about how to deal with pain, and the need for information and clarification may vary. The aim of this study is to enhance pain management by academic detailing (patients' current knowledge and motivations are the basis for information) and nurse coaching (frequent and individualized support). The study consists of 4 phases; (1) a pilot study about patients experience with pain after surgery by a structured telephone interview; (2) development of an intervention to improve pain management; (3) implement and evaluate the intervention; (4) evaluate the incidence of chronic pain after day surgery. Even if patients are prescribed sufficient doses of analgesics, pain relief is dependent on patients' adherence with the analgesic regimen. Psychological factors, such as catastrophizing may also contribute to patients' experience of postoperative pain. Strategies that may be more effective than general information concerning surgery and pain management is academic detailing and nurse coaching, and will be used as frame for the intervention.

Hypothesis:

Over the seven days after surgery patients in the intervention group report;

* higher adherence with the analgesic regimen,
* have less pain intensity and pain interference with function and
* lower severity of side effects compared to the control group.


Eligibility Criteria:
Inclusion Criteria:

* \> 18 years of age;
* able, to read, write, and understand Norwegian;
* are scheduled for orthopedic (shoulder, bunnies), or breast reconstruction surgery and
* have a telephone line.

Exclusion Criteria:

* Staying overnight in hospital
Tricuspid Cardiopulmonary Exercise Study

Tricuspid regurgitation (TR), which in close to 90% of cases is functional as a consequence of left-sided heart failure, left heart valve abnormalities or pulmonary (vascular) disease, is associated with adverse patient outcomes . Due to the increased risk of surgical tricuspid valve repair or replacement compared to surgery in left-sided valve disease TR is often undertreated. Treatment options for the tricuspid valve have so far been limited. Conservative therapy over longer. periods usually results in refractoriness to diuretic treatment. Surgical therapy is associated with a high rate of in-hospital mortality (8.8%), the cause of which is not yet fully understood but may partly be explained by the hemodynamic challenge that cardiopulmonary bypass imposes on the often already-dysfunctional right ventricle. Recently, transcatheter strategies have been developed and have shown promising results. Despite the promising data it has so far not be determined objectively whether interventional treatment of isolated tricuspid regurgitation improves exercise capacity and what role right ventricular function plays in this setting.


Eligibility Criteria:
Inclusion Criteria:

* Chronic tricuspid regurgitation 2+ to 4+ on a scale of 4+ (moderate to severe) with annular diameter ≥ 40 mm with valve systolic pulmonary pressure (sPAP) ≤ 60 mmHg
* New York Heart Association (NYHA) Class II-IV
* Symptomatic despite Guideline Directed Medical Therapy (GDMT); at minimum patient on diuretic regimen
* Left ventricular ejection fraction ≥ 30%
* Symptomatic despite Guideline Directed Medical Therapy (GDMT); at minimum patient on diuretic regimen
* The local site Heart Team concur that surgery will not be offered as a treatment option
* Written informed consent in accordance with Good Clinical Practice (GCP) and local legislation

Exclusion Criteria:

* Inability to perform cardiopulmonary exercise test
* Aortic, mitral and/or pulmonic valve stenosis and/or regurgitation ≥ moderate
* Previous tricuspid valve repair or replacement
* Severe precapillary pulmonary hypertension (PVR\>6 WE)
* Cerebrovascular accident (CVA) within the past 6 months
* Presence of trans-tricuspid pacemaker or defibrillator leads which cause impingement of the tricuspid valve leaflet as evaluated by echocardiography
* Subject is on chronic dialysis and/or anemia (Hb \< 9 g/L)
* Myocardial infarction or known unstable angina within 30 days prior to the index procedure
* Any percutaneous coronary intervention or transcatheter valvular intervention within 30 days prior to the index procedure or planned 3 months post the index procedure
* Previous tricuspid valve repair or replacement
* Life expectancy of less than 12 months
* Patients with cardiac cachexia
* Echocardiographic evaluation not available or not suitable for analysis at baseline
* Unsuitable anatomy for transcatheter tricuspid intervention
* Key information from patients (e.g. NYHA, TR grade) not available
* Known allergy or intolerance against the studied device
* Persons held in an institution by legal or official order
Myocardial Oedema in ST Segment Elevation Myocardial Infarction Myocardial

Cardiac magnetic resonance imaging (CMR) is a non invasive technique used to obtain functional and anatomical information on the heart. Several CMR parameters measured after primary percutaneous coronary intervention (PPCI) have been shown to have prognostic value and are increasingly being used as surrogate endpoints in clinical trials. Myocardial oedema is a prognostic indicator following myocardial infarction1. Myocardial salvage is calculated as the myocardial oedema minus infarct size; this again is a prognostic indicator following STEMI. However, myocardial oedema imaging is controversial. There are multiple sequences available, with no standardisation of sequences used to assess this surrogate endpoint. The investigators propose to conduct a study to measure the myocardial oedema by all available techniques to determine the agreement between these methods.


Eligibility Criteria:
Inclusion Criteria:

* STEMI
* providing written informed consent

Exclusion Criteria:

* contraindication to CMR,
* atrial fibrillation,
* claustrophobia,
* eGFR \< 30
Healing At Home 2.0 - Enhanced Chat Tool for Lowering Postpartum Depression

The purpose of the study is to determine if access to a text-message based holistic chatbot support program "Healing at Home 2.0" decreases depressive symptoms as measured by the Edinburgh Postnatal Depression Scale (EPDS) compared to usual postpartum care for patients of color.

Healing at Home (H@H) 2.0 is a comprehensive technology-based postpartum support program which provides 24/7 support to individuals through use of an SMS chatbot for six weeks postpartum. This will be a randomized controlled trial (RCT) with an intervention arm consisting of patients who are planning to be discharged at routine timing (as determined by their clinical team) with access to H@H 2.0 postpartum SMS chatbot platform and a control arm which consists of usual postpartum care.

Eligibility Criteria:
Inclusion Criteria:

* Postpartum patients who have delivered a singleton baby at or after 37w0d at the Hospital of the University of Pennsylvania
* Self-identify as a person of color (listed on chart as non-White race and confirmed with patient)
* Able to speak, read and write English
* Age ≥18
* Prenatal care at outpatient practice affiliated with the Hospital of the University of Pennsylvania
* Completion of clinically administered EPDS during inpatient stay
* Routine discharge timing, day 2 or more after vaginal delivery, day 3 or more after cesarean delivery

Exclusion Criteria:

* Unable to provide informed consent
* Baby not discharged with mother at postpartum discharge
* Does not have access to a mobile phone